𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer

✍ Scribed by Noa Ben-Baruch; Andrea M. Denicoff; Barry R. Goldspiel; Joyce A. O'Shaughnessy; Kenneth H. Cowan

Publisher
Springer US
Year
1993
Tongue
English
Weight
323 KB
Volume
11
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of ionidamine in patients
Phase II study of ionidamine in patients with metastatic breast cancer
✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi

Phase II study of subcutaneously adminis
Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma
✍ Bellet, Robert E. ;Catalano, R. B. ;Mastrangelo, Michael J. ;Berd, David πŸ“‚ Article πŸ“… 1978 πŸ› John Wiley and Sons 🌐 English βš– 268 KB

## Abstract Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC‐45388) and a nitrosourea were treated with 5‐azacytidine (NSC‐102816). 5‐Azacytidine was administered subcutaneously at a dosage of 100 mg/m^2^/day for 10 days. Twenty‐six (26) patients were evaluab